Skip to content
Dr. Tashko’s badge from the Better Business Bureau displays an “Accredited Business” seal with an A+ rating as of July 9, 2025 for GT Health practice. The design features the BBB torch logo on the left and a clickable prompt for profile access on the right, reinforcing professional credibility, transparency, and excellence in patient care and business ethics.
🗨️ Text Us Securely

Fees | Join Our Practice

  • Home
  • Dr. Tashko
    • Profile
    • My Philosophy
    • Featured in Montgomery Magazine
    • Featured in Washingtonian
    • Publications
  • Reviews
  • Benefits
    • Personalized & Integrative Care
    • Our Unique Approach
    • FAQs
  • Services
    • Endocrinology
    • Diabetes
    • Lipidology
    • Hypertension
    • Weight Loss
    • Heart
    • Women’s Health
    • Testosterone, TRT
    • Thyroid
    • Parathyroid
    • Adrenal
    • Pituitary
    • Gynecomastia
    • PCOS
    • Osteoporosis
    • Calcium
    • Longevity
    • Clinical Trials
    • Energy Metabolism
    • Fitness
    • More…
  • Become a Patient
    • Join Our Practice
    • Fees
    • A Letter to My Patients
  • Resources
    • Articles and Posts
    • Key Clinical Trials
    • Clinical Guidelines
    • Personal Interests
    • Search 🔎
  • Contact Us

GLP-1 And GIP Dual Agonist Therapy

  • Why the FDA Approved Mounjaro for Children Age 10+ with Type 2 Diabetes

    Why the FDA Approved Mounjaro for Children Age 10+ with Type 2 Diabetes

    The FDA approval of Mounjaro for children age 10 and older reflects a major shift in pediatric type 2 diabetes care. New evidence shows meaningful A1c reduction and weight improvement in youth, addressing insulin resistance and appetite biology together. This article explains why the FDA approved tirzepatide, what the studies showed, and how this decision fits into modern metabolic care.

    Published

    January 4, 2026
    Categorized as Child Health, Diabetes Care, Dr. Tashko’s Key Clinical Trials, FDA Approvals, Insights from Dr. Tashko, Metabolic Care

The only US physician board-certified in:

❥ Endocrinology, Diabetes and Metabolism

❥ Obesity Medicine

❥ Hypertension

❥ Lipidology

Dr. Tashko’s badge from the Better Business Bureau displays an “Accredited Business” seal with an A+ rating as of July 9, 2025 for GT Health practice. The design features the BBB torch logo on the left and a clickable prompt for profile access on the right, reinforcing professional credibility, transparency, and excellence in patient care and business ethics.
🗨️ Text Our Office Securely

T

301.658.3586

F

240.427.4704

E

admin@GThealth.net

15204 Omega Drive
Suite 240
Rockville, MD 20850

Dr. Tashko is quadruple board-certified in endocrinology, lipidology, hypertension, and obesity medicine. He specializes in diabetes, metabolism, and longevity care, offering integrative, evidence-based solutions for insulin resistance, metabolic syndrome, prediabetes, obesity, and weight management.

He provides advanced cardiovascular prevention and lipid management, focusing on precise control of blood pressure, cholesterol, and triglycerides.

His endocrine expertise covers thyroid and parathyroid disorders, pituitary and adrenal conditions, growth hormone deficiency, Cushing’s syndrome, hyperprolactinemia, and bone health issues such as osteopenia and osteoporosis.

Dr. Tashko also treats low testosterone (TRT), gynecomastia, and polycystic ovary syndrome (PCOS). Each patient receives comprehensive, personalized care centered on metabolic and hormonal balance.

GT Health is based in Rockville, Montgomery County, MD, and serves patients throughout Bethesda, Chevy Chase, Potomac, Gaithersburg, Germantown, Frederick, Silver Spring, Howard County, Anne Arundel, Northern Virginia, and the Eastern Shore. GT Health provides concierge endocrine and metabolic care in Rockville and across Maryland through secure virtual visits.

Medical Conditions
  • Facebook
  • Google
  • LinkedIn
  • Twitter

Copyright

© 2017–2026

Gerti Tashko, M.D.

All Rights Reserved.

“In him all things hold together.”
— Col 1:17